PANAGIOTIS D. TSIRIGOTIS

Professor in Hematology

CURRICULUM VITAE

October 2026

LIST OF CONTENTS

BRIEF DESCRIPTION OF MY WORK **3**

1. PERSONAL DATA 4

2. GRADUATE EDUCATION 4

3. POSTGRADUATE TRAINING AND EDUCATION 4

4. HOSPITAL POSITIONS 5

5. TEACHING ACTIVITIES AND EXPERIENCE 6

6. CLINICAL EXPERIENCE 6

7. RESEARCH WORK 7

8. SCIENTIFIC SOCIETIES AND COMMITTEES 13

9. EDITORIAL WORK 14

10. ADMINISTRATIVE AND ORGANIZING EXPERIENCE 16

11. PARTICIPATION IN SCIENTIFIC CONGRESSES/MEETINGS 17

BRIEF DESCRIPTION OF MY WORK

Currently I am Professor in Hematology in 2nd Department of Internal Medicine at ''ATTIKO'' General University Hospital, Head of the Hematology Division and Principal Investigator of the Bone Marrow Transplantation (BMT) Program.

I graduated from the National and Kapodistrian University of Athens, in 1989.

I completed my post graduate training in Hematology at ''EVANGELISMOS'' General Hospital in 1999.

During my fellowship in Israel (Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah University Medical Center, Jerusalem, Israel, Prof Shimon Slavin). I was involved in clinical research focused on allogeneic hematopoietic stem cell transplantation using reduced intensity conditioning, and on cancer immunotherapy, and I established a fruitful collaboration which is still ongoing.

From 2005 and till today, I am an active staff member of 2nd Dept of Internal Medicine at ''ATTIKO'' University Hospital.

In 2009, I was elected as a Lecturer, in 2012, I was elected Assistant Professor. In 2018, I was elected Associate Professor and finally in March/2022, I was elected Professor in Hematology.

I was the major contributor for the establishment of the BMT Unit at ''ATTIKO'' Hospital. In 2005, the Unit performed only autologous-SCT, and now runs a fully accredited allogeneic BMT Program (CIC-604). Currently our Unit is one the four transplant centers in Greece which perform both related and unrelated transplants as well as treatment with CART-cells and is a referral center for many hospitals all over Greece. In addition our Unit has been selected as a Donor Center responsible for stem cell graft collection for unrelated donors.

I am elected Vice President of the Hellenic Society of Hematology and General Secretary of the Acute Leukemia and Myelohyperplastic Neoplasms Working Party. I was invited speaker in more than 100 scientific meetings at National and International level. Iam member of the Editorial Board and act as an expert reviewer in many peer-reviewed international scientific journals. I was member of the Organizing and Scientific Committee of many National and International meetings and congresses. Since 2021, Iam Vice-President of the Hellenic Transplant Organization.

I am Author of 163 original publications in SCI-Journals (first, second, or last author in 55%). In more detail, the total IF=515.753, the mean IF=5.405, the total number of citations=4.194, and the h-index=37.

CURRICULUM VITAE

1. PERSONAL DATA

Full Name: Panagiotis D. Tsirigotis

Date of Birth: 16/11/1964

Place of Birth: Agia Paraskevi, Athens

Nationality: Greek

Contact Information

Home: Kikladon-45, Agia Paraskevi, Athens, PO:15341

E-mail: panagtsirigotis@gmail.com, pantsir@med.uoa.gr

Hospital office: 2nd Department of Internal Medicine, Propaudeutic, ATTIKO

University Hospital, Rimini-1, Haidari, 12461

Phone: +30-210-5832317, +30-210-5831342

Cell phone: +30-6944-618814

Fax: +30-210-5832728

Present Position

Professor in Hematology, 2nd Department of Internal Medicine Propaudeutic, National and Kapodistrian University of Athens, ATTIKO General University Hospital, Athens, Greece

2. GRADUATE EDUCATION

1982-1989: MD, National and Kapodistrian University of Athens, Medical School

3. POSTGRADUATE TRAINING AND EDUCATION

1990 – 1992: Primary care physician (Rural Medical Service) National Health System

1992 - 1994: Resident in Internal Medicine,

1994 - 1998: Resident in Hematology

1998: Degree in Hematology (Greek Boards in Hematology)

1999 – 2004: DCs, Medical School of National and Kapodistrian University of Athens.

4. HOSPITAL POSITIONS

2000 - 2004: Attending Hematologist, Division of Hematology, 3rd Department of Internal Medicine, 1st Hospital of Social Insurance Foundation, Athens.

2004 - 2006: Fellow in Bone Marrow Transplantation. Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah University Medical Center, Jerusalem, Israel (Chairman and Director: Prof Shimon Slavin).

2006 - 2009: Attending, 2nd Department of Internal Medicine – Propaudeutic, (Hematology and Bone Marrow Transplantation Unit), National and Kapodistrian University of Athens.

2009 – 2012: Lecturer in Hematology, 2nd Department of Internal Medicine – Propaudeutic, (Hematology and Bone Marrow Transplantation Unit), National and Kapodistrian University of Athens.

2012 – 2018: Assistant Professor in hematology.

2018 – 2022: Associate Professor in Hematology, and

2022 – present: Professor in Hematology, 2nd Department of Internal Medicine – Propaudeutic, (Hematology and Bone Marrow Transplantation Unit), National and Kapodistrian University of Athens.

Licensure and Certification

March – 1989: Medical Licence in Greece

January – 1999: Certified Diplomate in Hematology

June – 2004: Doctoral Thesis: «Mutation analysis of p16 gene in patients with chronic lymphocytic leukemia», National and Kapodistrian University of Athens, School of Medicine, Grades: ‘‘Excellent’’

Languages

English

5. TEACHING ACTIVITIES AND EXPERIENCE

Throughout the course of my medical career I have been actively involved in the education of students and young doctors.

4/2004 – continued: teaching in medical students. Clinical examination and differential diagnosis in Internal Medicine (lectures and bedside teaching)

4/2004 – continued: teaching in medical students. Basics in Hematology (lectures and bedside teaching)

4/2004 – continued: teaching in residents of Internal Medicine. Basics in Hematology

4/2004 – continued: teaching in residents of Hematology. All aspects of Hematology

3/2012 – continued: I actively participate in the educational program of the Hellenic Society of Hematology (teaching in residents of Hematology with special emphasis in the field of acute leukemias and bone marrow transplantation).

Teaching in master courses

2013 – continued: teaching in master course organized by the National and Kapodistrian University of Athens: Intensive care unit and urgent nursing

2013 – continued: teaching in master course organized by the National and Kapodistrian University of Athens: Thrombosis, haemorrhage and transfusion medicine

6. CLINICAL EXPERIENCE

Throughout the course of my medical career the focus of my interest was clinical work, in order to provide health services to patients according to the respective positions I held. In all positions, I have fully participated in the working activities and the scientific program.

During the last 25 years, I was responsible for the management of patients with a variety of diseases covering all the areas of benign and malignant hematology, with special emphasis in leukemias and Bone Marrow Transplantation.

2004 – up to day: As a member of the faculty of the 2nd Department of Internal Medicine, Propaudeutic of the National and Kapodistrian University of Athens, iam actively involved in all fields of clinical hematology, with special emphasis in the field of leukemias and hematopoietic stem cell transplantation.

Myself and in collaboration with my team established a fully accredited allogeneic Bone Marrow Transplant (BMT) Program, which currently performs all types of transplants.

I am Head of the Hematology Division and the director of the BMT Program of the 2nd Department of Internal Medicine. The BMT Unit of our Department at ATTIKO was founded in 2004, and is affiliated to European Blood and Marrow Transplantation (EBMT) society with the code CIC- 604.

7. RESEARCH WORK

Since 2010 I participated as Principal Investigator in 31 Multicenter International Clinical Trials. Below there is a list of the clinical trials since 2019.

7.1 Principal Investigator in Clinical Trials

- A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL). Clinical Trial NCT05933070.
- PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R-CHOP VERSUS R-CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): EPCORE DLBCL-2. NCT05578976
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib. NCT04485260
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1).
- MANIFEST-2 Study of Pelabresib Plus Ruxolitinib Completes Enrollment in Myelofibrosis. (NCT04603495)
- A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia. IDNCT05211570.
- A Study to Evaluate the Pharmacokinetics (PK), Efficacy and Safety and Tolerability of Pegcetacoplan in Patients With TA-TMA After Hematopoietic Stem Cell Transplantation (HSCT). NCT05148299
- A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML). NCT04161885.

- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor (JAKi)-naïve Myelofibrosis and Moderate Thrombocytopenia. NCT05980806
- A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201). NCT04710576
- Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). NCT02227251
- A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia.
- A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant recipients. NCT02927067
- Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant. NCT04543591
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Adult Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract. 2020-002213-18
- Multicenter randomized, double blind controlled study of BTK inhibitor (Ibrutinib) in combination with Rituximab versus Placebo in combination with Rituximab in newly diagnosed patients with follicular lymphoma.
- Multicenter randomized, double blind controlled phase III study of FLT3-inhibitor Gilteritinib as maintenance after allogeneic stem cell transplantation versus maintenance with placebo in patients with AML and FLT3-ITD mutation.
- Multicenter randomized, double blind controlled phase III study of itacitinib or placebo in combination with corticosteroids as first line treatment in patients with acute graft versus host disease. (GRAVITAS-301).
- An observational study of safety and efficacy of blinatumomab in standard clinical care.
- Randomized, multicenter open label, phase III study of ruxolitinib versus best supportive care in patients with corticosteroid resistant chroniv graft versus host disease after allogeneic stem cell transplantation. (REACH 3).

- A Phase 2, Prospective, Randomized, Open-Label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant.
- GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease.
- Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation.
- Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S Maintenance Therapy Compared to Best Available Therapy in Acute Myeloid Leukemia Patients Who Have Achieved Complete Remission After Second-Line Salvage Therapy.
- A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML).

7.2. Research Thesis

''Mutation analysis of p16 gene in patients with chronic lymphocytic leukemia'' (DCs) 2nd Department of Internal Medicine – Propaudeutic, Medical School of National and Kapodistrian University of Athens

7.3. Publications in peer reviewed international journals

I am Author of 163 original publications in SCI-Journals (first, second, or last author in 55%). In more detail, the total IF=515.753, the mean IF=5.405, the total number of citations=4.194, and the h-index=37.

Below there is a list of publications since 2021

1: Kastritis E, Filippatos C, Gavriatopoulou M, Theodorakakou F, Solia E, Ntanasis-Stathopoulos I, Malandrakis P, Kanellias N, Eleutherakis-Papaiakovou E, Migkou M, Spiliopoulou V, Katsadouros I, Vlachou A, Fotiou D, Giannakas K, Boutakoglou E, Giannouli S, **Tsirigotis P**, Papanikolaou A, Terpos E, Dimopoulos MA. Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients. Hemasphere. 2026 Aug 6;10(8):e70435.

2: Solia E, Theodorakakou F, Malandrakis P, Ntanasis-Stathopoulos I, Kanellias N, Eleutherakis-Papaiakovou E, Migkou M, Spiliopoulou V, Katsadouros I, Giannakas K, Giannouli S, **Tsirigotis P**, Papanikolaou A, Fotiou D, Gavriatopoulou M, Terpos E, Dimopoulos MA, Kastritis E. Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies. Br J Haematol. 2026 Sep;209(3):1068-1075.

3: Grosicki S, Yimer H, Ayala R, Chen S, Liu H, Boyer F, Guglielmelli P, Brociner M, Sportoletti P, Mikala G, **Tsirigotis P**, Zhang J, Mark T, Chai Y, Ellero A, Lucchesi A. Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT-035 Study. EJHaem. 026 Jun 1;7(3):e70301.

4: **Tsirigotis P**, Lazana I, Chatzidimitriou C, Shaver L, Konstantellos I, Mohty R, Gkolfinopoulou G, Stamouli M, Espinoza-Gutarra M, Karagiannidou A, Sharma A, Chondropoulos S, Gkirkas K, Jamy O. Gilteritinib for Prevention of Post-transplant Relapse in Patients With Acute Myeloid Leukemia and FLT3-ITD Mutation: Real-Life Data from Two Centers. Transplant Cell Ther. 2026 Jul;32(7):852.e1-852.e3.

5: **Tsirigotis P**, Garofalaki M, Lazana I, Liga M, Gigantes S, Kopsaftopoulou A, Tziotziou E, Roumelioti A, Tsintziloni E, Hatzis S, Konstantellos I, Benetatos L, Barbarousi D, Tzenou T, Asimakopoulos JV, Karagiannidi A, Barakos G, Delimpasi S, Stoumbos D, Stamouli M, Plata E, Valera K, Giannouli S, Chatzidimitriou C, Gkolfinopoulou G, Siakantaris MP, Kotsopoulou M, Voulgarelis M, Chondropoulos S, Zina V, Gkirkas K, Kapsali E, Matsouka C, Vassilakopoulos TP, Spyridonidis A, Angelopoulou M, Baltadakis I. Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse. Am J Hematol. 2026 Jul;101(7):1543-1553.

6: Kazakou P, Charalampidis C, Konstantellos I, Gkirkas K, Stamouli M, Lazana I, Chatzidimitriou C, Gkolfinopoulou G, Chondropoulos S, Mastrostamati E, Grigoropoulos I, Georgiou PC, Karakosta P, Katechis S, Pournaras S, Kavatha D, **Tsirigotis P**, Tsiodras S, Thomas K. Rectal Colonization with Multidrug-Resistant Organisms and Subsequent Bloodstream Infections in Hematological Patients Undergoing Cellular Therapies. Transplant Cell Ther. 2026 Jul;32(7):899.e1-899.e12.

7: Lazana I, Gkirkas K, Konstantellos I, Chatzidimitriou C, Karagiannidou A, Gkolfinopoulou G, Stamouli M, Chondropoulos S, **Tsirigotis P.** Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity. Bone Marrow Transplant. 2026 Jan;61(1):59-66.

8: **Tsirigotis P**, Lazana I. Donor-derived malignancy after allogeneic stem cell transplantation: a rare but well recognized complication. Bone Marrow Transplant. 2025 Nov;60(11):1417-1425.

9: Triantafyllou AS, Sterpi AE, Theodorou A, Chondrogianni M, Papagiannopoulou G, Tsikalakis G, Palaiodimou L, Foukas PG, Skarentzos K, Moschovos C, Magoufis G, Lachanis SB, **Tsirigotis P**, Tsivgoulis G. Patient With Bilateral Infracts and Vasculitis With Graft vs Host Disease. Neurology. 2025 Oct 21;105(8):e214216.

10: Gavriilaki E, Tzannou I, Batsis I, Tsonis I, Liga M, Gkirkas K, Ximeri M, Dolgyras P, Bampali V, Evangelidis P, Bousiou Z, Vardi A, Demosthenous C, Stroggyli E, Bouzani M, Sagiadinou E, Mallouri D, Tzenou T, Sotiropoulos D, Gigantes S, Anagnostopoulos A, Karakasis D, Papadaki H, **Tsirigotis P**, Spyridonidis A, Vassilakopoulos T, Angelopoulou M, Sakellari I, Baltadakis I. EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy. Blood Vessel Thromb Hemost. 2024 Aug 21;1(4):100025.

11: Lazana I, Papathanassiou M, Konstantellos I, Tzenou T, Kopsaftopoulou A, Liga M, Violaki V, Kyriazopoulou L, Gkirkas K, Papalexandri A, Plata E, Michalis E, Leonidopoulou T, Garofalaki M, Sioni A, Tziotziou I, Lalayanni C, Kiousiafes D, Vassilakopoulos TP, Kapsali E, Spyridonidis A, Baltadakis I, Angelopoulou M, Sakellari I, **Tsirigotis P**. The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry. Cancers (Basel). 2025 Feb 16;17(4):667.

12: Chantziou A, Brenna C, Ioannidou K, Chen OY, Korkolopoulou P, Antoniadou A, Psichogiou M, Papaioannou M, **Tsirigotis P**, Foukas PG, de Leval L, Petrovas C. HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma. Blood Adv. 2024 Dec 24;8(24):6215-6231.

13: Eleutherakis Papaiakovou E, Terpos E, Kanellias N, Migkou M, Gavriatopoulou M, Ntanasis-Stathopoulos I, Fotiou D, Malandrakis P, Theodorakakou F, Spiliopoulou V, Kostopoulos IV, Tsitsiloni O, **Tsirigotis P,** Dimopoulos MA, Kastritis E. Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation. Leuk Lymphoma. 2023 Dec;64(13):2140-2147.

14: Rampotas A, Sockel K, Panitsas F, Theuser C, Bornhauser M, Hernani R, Hernandez-Boluda JC, Esquirol A, Avenoso D, **Tsirigotis P,** Robin M, Czerw T, Helbig G, Roddie C, Lambert J, McLornan DP. Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study. Transplant Cell Ther. 2023 Nov;29(11):687.e1-687.e7.

15: **Tsirigotis P**, Spyridonidis A, Gkirkas K, Chondropoulos S, Rondogianni P, Thomopoulos T, Karagiannidou A, Vythoulkas D, Griniezaki M, Georgakopoulos N, Stamouli M, Foukas PG. Solid tumor transmission from donor to recipient after allogeneic stem cell transplantation: it is rare but it happens! Blood Transfus.2023 Sep;21(5):437-440.

16: Vythoulkas D, Lazana I, Kroupis C, Gavriilaki E, Konstantellos I, Bousiou Z, Chondropoulos S, Griniezaki M, Vardi A, Gkirkas K, Karagiannidou A, Batsis I, Stamouli M, Sakellari I, **Tsirigotis P.** Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor. Int J Mol Sci. 2023 Apr 9;24(8):6960.

17: Symeonidis A, Chondropoulos S, Verigou E, Lazaris V, Kourakli A, **Tsirigotis P.** Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders. Front Oncol. 2022 Aug 5;12:884723.

18: Swan D, Hayden PJ, Eikema DJ, Koster L, Sauer S, Blaise D, Nicholson E, Rabin N, Touzeau C, Byrne J, Huynh A, Cornelissen JJ, Potter V, Forcade E, Parrish C, Gribben J, Chretien ML, Mielke S, Gedde-Dahl T, Reményi P, **Tsirigotis P**, Garcia Guiñón A, Beksac M, Schönland S, Yakoub-Agha I. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. Br J Haematol. 2022 Apr;197(1):82-96.

19: Hernández-Boluda JC, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden JA, **Tsirigotis P,** Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan DP, Yakoub-Agha I. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplant. 2022 Mar;57(3):416-422.

20: Stamouli M, Gkirkas K, Karagiannidi A, Iliakis T, Chondropoulos S, Thomopoulos T, Nikolaou V, Pappa V, Papadavid E, **Tsirigotis P**. Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas. Clin Hematol Int. 2021 Jun 12;3(2):72-76.

21: **Tsirigotis P**, Gkirkas K, Kitsiou V, Chondropoulos S, Athanassiades T, Thomopoulos T, Tsirogianni A, Stamouli M, Karagiannidi A, Siafakas N, Pappa V, Nagler A. Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia. Cancers (Basel). 2021 May 30;13(11):2699.

22: Styczyński J, Tridello G, Xhaard A, Medinger M, Mielke S, Taskinen M, Blijlevens N, Rodriguez MAB, Solano C, Nikolousis E, Biffi A, Groll AH, Junghanss C, **Tsirigotis P**, Lioure B, Šrámek J, Holler E, Galaverna F, Fagioli F, Knelange N, Wendel L, Gil L, de la Camara R, Mikulska M, Ljungman P. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. Bone Marrow Transplant. 2021 May;56(5):1171-1179.

23: Stamouli M, Tsonis I, Gkirkas K, Economopoulou C, Siafakas N, Pournaras S, Antoniadou A, Chondropoulos S, Karagiannidi A, Meletiadis J, Gigantes S, Baltadakis I, Goussetis E, Karakasis D, **Tsirigotis P**. Oral ribavirin is a highly effective treatment for lower respiratory tract infections due to respiratory syncytial virus or parainfluenza after allogeneic stem cell transplantation. Bone Marrow Transplant. 2021 Feb;56(2):511-513.

24: Gkirkas K, Stamouli M, Karagiannidou A, Chondropoulos S, **Tsirigotis P**. Extramedullary leukemia relapse after allogeneic stem cell transplantation: a novel mechanism of immune escape? Immunotherapy. 2020 Jun;12(9):635-640.

8. MEMBER OF SCIENTIFIC SOCIETIES AND COMMITTEES

8.1. Hellenic Societies and Committees

1. Hellenic Society of Hematology
2. Hellenic Society of Hemapheresis
3. Hellenic Society of Gene and Regenerative Medicine

4. Member of the Hellenic Society of Hematology Administrative Council

(November/2008 – November/2012, and November/2014 – continued)

5. Member of the Administrative Board of Acute Leukemia and Myelohyperplastic Neoplasms Working Party of the Hellenic Society of Hematology (November/2007 – continued)

8.2. International Societies and Committees

1. Israeli Medical World Fellowship
2. European Group for Blood and Bone Marrow Transplantation

9. EDITORIAL WORK

I am a member of the Editorial Board of «AIMA», the official journal of the Hellenic Society of Haematology. Iam also a member in the Editorial Board and I have been a reviewer in international journals (listed below).

Editorial Board Membership

1) Case Reports in Hematology

2) Biomed Research International (IF=1.579)

3) Advances in Medicine

4) Case Reports in Internal Medicine

Reviewer in peer-reviewed journals

1) Bone Marrow Transplantation (IF=3.570)

2) Cytotherapy (IF=3.293)

3) Expert Opinion on Biological Therapy (IF=3.743)

4) Archives of Gynecology and Obstetrics (IF=1.364)

5) Bio Drugs (IF=2.989)

6) Current Drug Metabolism (IF=3.554)

7) American Journal of Hematology (IF=3.798)

8) Case Reports In Hematology

9) Acta Hematologica (IF=0.994)

10) Biology of Blood and Marrow Transplantation (IF=3.404)

11) Case Reports in Internal Medicine

12) Immunotherapy (IF=2.070)

13) International Journal of Molecular Sciences (IF=2.862)

14) Journal of Blood Disorders

15) Journal of Hematology Oncology (IF=4.81)

16) Journal of Thrombosis and Hemostasis (IF=5.72)

17) World Journal of Gastrenterology (IF=2.37)

18) (MEMO) Magazine of European Medical Oncology

Author of Chapters in Books or Monographs

1. P. Tsirigotis. Mutational analysis of p16 gene in patients with chronic lymphocytic leukemia (2004). Doctoral Thesis.
2. Book: Alcoholism – Clinical management by E. Lycouras, Publisher: BITA (2007). I have contributed to chapter: P. Tsirigotis, J. Dervenoulas. Alcohol and hematopoiesis.
3. Book: Malignant hematologic diseases by T. Economopoulos, Publisher: Paschalidis – (2009). I have contributed to the following chapters: i) P. Tsirigotis. Acute Myeloid Leukemia, ii) Acute Promyelocytic Leukemia, iii) Acute Lymphoblastic Leukemia, iv) Allogeneic hematopoietic stem cell transplantation, v) Autologous stem cell transplantation.
4. Book: Clinical Pharmacology, Hematological malignancies, head and neck cancer, by Hellenic Academy of Oncology, (2009). I have contributed to chapter: P. Tsirigotis. Non-Hodgkin Lymphoma: Treatment and Follow up.
5. Book: New Insights in Hematopoietic Cell Transplantation by Alexandros Spyridonidis. Publisher: Research Signpost (2008) Chapter 12: Allogeneic cell immunotherapy for the treatment of malignant disorders, by P. Tsirigotis and J. Dervenoulas.
6. Book: PET/CT in Lymphomas: A Case-Based Atlas by JA. Andreou, PA. Kosmidis, AD. Gouliamos, In Collaboration with E. Vrakidou, VK. Prassopoulos, TP. Vassilakopoulos. Publisher: Springer (in press). Chapter: P. Tsirigotis, N.D. Papathanasiou, A.C Rousakis. Highly aggressive lymphomas.
7. Book: I have contributed 2 chapters (in the forthcoming edition) written in Greek to the official Textbook of Internal Medicine, which is used by the medical students of the National and Kapodistrian University of Athens. The topics include “Hemolytic Anemias” and “Bone Marrow Transplantation – HLA- system”.
8. I have contributed 3 chapters in 2 Books written in Greece and published by the National and Kapodistrian University of Athens and devoted to Prof. Alkiviadis Kostakis and Prof. Ioannis Meletis.

10. ADMINISTRATIVE AND ORGANIZING EXPERIENCE

- From November/2008 to November/2012 and from November/2014 till today, I am an elected member of the Administrative Council of the Hellenic Society of Hematology.
- From 2007 till today, I am an elected member of the Acute Leukemia and Myelohyperplastic Neoplasms Working Party of the Hellenic Society of Hematology, in which I am currently the general secretary.
- Furthermore, I have participated in the Organizing and/or Scientific committee of 6 National and 4 International Congresses.

- May/2017 – present: Member of the Advisory Board of the Hellenic Transplant Organization.
- May/2020 – present: Vice President of the Advisory Board of the Hellenic Transplant Organization.

Organizing – Scientific Committees

A. International Meetings

1. Member of the organizing and scientific committee: Symposium on Gene and Cell Therapy. September, 2014, University of Patras, Rio.
2. Member of the organizing and scientific committee: Medical Oncology and Hematology Board Review Course. January 2015, Athens, Greece

3. Member of the Organizing Committee of the Aegean Hematology Oncology Symposium (AHOS), 17-20 September 2015, Chios, Greece.

4. Member of the Organizing Committee and Faculty Member of the "Postgraduate Athens Lymphoma Seminar", 15-17 October 2015, Athens, **Greece.**

5. Member of the Organizing Committee of the 3rd Aegean Hematology Oncology Symposium (AHOS), September 2016, Thessaloniki, Greece.
6. Member of the Scientific Committee of the 4th Aegean Hematology Oncology Symposium (AHOS), September 2017, Rhodos, Greece.
7. Member of the Scientific Committee of the 5th Aegean Hematology Oncology Symposium (AHOS), September 2018, Port Cheli, Greece.
8. Member of the Scientific Committee of the 6th Aegean Hematology Oncology Symposium (AHOS), September 2019, Izmir, Turkey.
9. Member of the Scientific Committee of the 7th Aegean Hematology Oncology Symposium (AHOS), September 2020, WEB EVENT
10. Member of the Scientific Committee of the 8th Aegean Hematology Oncology Symposium (AHOS), September 2021, WEB EVENT
11. Member of the Scientific Committee of the 9th Aegean Hematology Oncology Symposium (AHOS), September 2022, Chios, Greece.
12. Member of the Scientific Committee of the 10th Aegean Hematology Oncology Symposium (AHOS), September 2023, Istanbul, Greece.
13. Member of the Scientific and Organizing Committee, 26th Infectious Diseases Working Party Educational Course of the EBMT, November, 2023, Athens, Greece

11. PARTICIPATION IN SCIENTIFIC CONGRESSES/MEETINGS

I have participated in >100 national or international congresses or meetings between 1994 and 2015. I have chaired many sessions in National and International congresses or meetings.

Interational congresses or meetings:

1. Meet the expert session in 12th International Congress on Hormonal Steroids and Hormones & Cancer, 13-16 September 2006, Athens, Greece. Title of session: New developments in Lymphoma Therapy. Title of lecture: Monoclonal antibodies in the treatment of lymphoid malignancies.
2. Title of Lecture: ''Stem cells: areas of established therapy; areas of vague benefit and areas of disappointing results''. 10th Congress of the European Federation of Internal Medicine. October – 2011, Athens, Greece.
3. Title of Lecture: Risk adapted treatment of adult acute myeloid leukemia. 2nd Aegean Hematology Oncology Symposium, Chios, 17-20 September 2015.
4. Title of Lecture: Cytonetic abnormalities in Philadelphia negative hematopoiesis. The 2nd CML Expert Exchange Experiences & Collaboration Meeting in Sophia, Bulgaria. May, 2015
5. Title of lecture: Minimal residual disease monitoring for clinical decision making in acute lymphoblastic leukemia: Pros and Cons. Panbalcanic Hematology Congress, October, 2015, Sophia, Bulgaria
6. Title of lecture: Risk adapted treatment in acute myeloid leukemia. Aegean Hematology Oncology Symposiumgy Symposium, Chios, 17-20 September 2015.
7. Title of lecture: Immunological approaches in patients with malignant diseases. Aegean Hematology Oncology Symposium, Thessaloniki, 17-20 September 2016.

8. Title of lecture: The role of allogeneic stem cell transplantation in acute promyelocytic leukemia. 4th Aegean Hematology Oncology Symposium, 21-24 September, 2017, Rhodes, Greece
9. MYELODYSPLASTIC SYNDROMES. Should Molecular Genetics Guide the Decision for Allogeneic Transplant? No: Panagiotis Tsirigotis. 5th Aegean Hematology Oncology Symposium, September, 2018, Porto Cheli, Greece
10. Incidence And Treatment Outcome of Lymphomas In HIV-Infected Patients: The Greek Experience. Panagiotis Tsirigotis, 6TH AHOS – 03 -06 OF OCTOBER 2019– Izmir, TURKEY
11. Chemotherapy free strategy for ph+ ALL? NO Panagiotis Tsirigotis, 6TH AHOS – 03 -06 OF OCTOBER 2019– Izmir, TURKEY
12. CAR-T therapy for lymphomas. Panagiotis Tsirigotis, 7TH AHOS –September, 2020 virtual meeting
13. All patients with intermediate-risk AML must be transplanted. NO Panagiotis Tsirigotis, 8TH AHOS 2021, September, Web meeting
14. Optimal management of elderly patients with acute myeloid leukemia. Panagiotis Tsirigotis. 1st Greco-Israeli Hematology Meeting, Thessaloniki, April, 2018
15. Title of lecture: FLT3 mutated acute myeloid leukemia: Treatment algorithm and practical tips. Panagiotis Tsirigotis, EHA-SRH-SHTRM Balkan Hematology Tutorial, April 2023, Bucharest, Romania
16. Title of lecture: Chimeric Antigen Receptor T-Cell Therapy in Adult B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant? Panagiotis Tsirigotis, EHA-Balkan Hematology Day 2023, October, 2023, Belgrade, Servia